Key Takeaways
- • London-based private equity firm Samfara completed its first acquisition, purchasing Danish pharmaceutical ingredients manufacturer Chr. Olesen Synthesis A/S for an undisclosed amount.
- • Chr. Olesen Synthesis has deteriorated financially, posting negative equity and losses in four of the past five years prior to the sale.
- • The acquisition marks Samfara's entry into the life sciences sector and represents a distressed asset recapitalization typical of PE playbooks targeting underperforming specialty pharma manufacturers.
Summary
Samfara, a London-based private equity fund, has completed its inaugural investment by acquiring Chr. Olesen Synthesis A/S, a Danish manufacturer of pharmaceutical ingredients. The transaction price was not disclosed by either party.
Chr. Olesen Synthesis had been struggling operationally and financially before the sale. The company carried negative equity on its balance sheet and incurred losses in four of the five years immediately preceding the acquisition, signaling sustained operational challenges and deteriorating financial condition typical of distressed asset targets.
The deal represents Samfara's first portfolio company and signals the fund's strategic focus on the life sciences sector, specifically pharmaceutical manufacturing. Acquisition of underperforming pharma ingredients makers aligns with established private equity strategies for turnarounds—targeting companies with operational inefficiencies, cost structures ripe for optimization, or market positioning that can be improved under new ownership and capital structure.
Chr. Olesen Synthesis had been struggling operationally and financially before the sale. The company carried negative equity on its balance sheet and incurred losses in four of the five years immediately preceding the acquisition, signaling sustained operational challenges and deteriorating financial condition typical of distressed asset targets.
The deal represents Samfara's first portfolio company and signals the fund's strategic focus on the life sciences sector, specifically pharmaceutical manufacturing. Acquisition of underperforming pharma ingredients makers aligns with established private equity strategies for turnarounds—targeting companies with operational inefficiencies, cost structures ripe for optimization, or market positioning that can be improved under new ownership and capital structure.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.